Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|May 28, 2026
Discovery of a Highly Potent and Efficient BRD9 Degrader with Strong In Vivo Antitumor ActivityXin Tang, Yumin Huang, Cheng Zhang, et al.
Cancer Research|February 11, 2010
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3Christopher P Guise, Maria R Abbattista, Rachelle S Singleton, et al.
Cancer Gene Therapy|February 9, 2021
Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumoursAlexandra M Mowday, Ludwig J Dubois, Aleksandra M Kubiak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104Adam V Patterson, Dianne M Ferry, Shelley J Edmunds, et al.
Journal of Medicinal Chemistry|September 8, 2025
Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical ResistanceWuqing Deng, Xiaojuan Chen, Ling Yan, et al.
Molecules (Basel, Switzerland)|October 27, 2020
Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic CytotoxicityChris P Guise, Maria R Abbattista, Robert F Anderson, et al.
Journal of Medicinal Chemistry|September 29, 2022
Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer CellsFang Xu, Xin Zhang, Zhipeng Chen, et al.
Journal of Medicinal Chemistry|February 13, 2024
Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma ActivityFang Yang, Qianmeng Lin, Xiaojuan Song, et al.
Biochemical Pharmacology|July 26, 2016
Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapyAlexandra M Mowday, Amir Ashoorzadeh, Elsie M Williams, et al.
Biochemical Pharmacology|February 13, 2013
Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104AGareth A Prosser, Janine N Copp, Alexandra M Mowday, et al.
Pageof 9